This trial is active, not recruiting.

Condition pulmonary disease, chronic obstructive
Treatment noninvasive positive pressure ventilation
Phase phase 3
Sponsor Groningen Research Institute for Asthma and COPD
Collaborator The Netherlands Asthma Foundation
Start date November 2004
End date April 2009
Trial size 100 participants
Trial identifier NCT00135538, RECOVER1


The purpose of this study is to investigate whether noninvasive ventilation by nose mask during the night has additional benefits next to pulmonary rehabilitation in patients with severe hypercapnic COPD.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking open label
Primary purpose treatment

Primary Outcomes

Health related quality of life measured by the Chronic Respiratory Questionnaire
time frame:

Secondary Outcomes

Activities of daily Living
time frame:
Dyspnea (Medical Research Council Scale [MRC], baseline dyspnea index [BDI], Borg)
time frame:
Exercise tolerance (Cycle ergometer test, 6-minute walk distance [6-MWD], incremental shuttle walking test [ISWT], endurance shuttle walking test [ESWT])
time frame:
Pulmonary function testing
time frame:
Sleep quality (polysomnography)
time frame:
Respiratory muscle activity (endurance shuttle walking test [EMG])
time frame:
Respiratory muscle strength (PImax, PEmax)
time frame:

Eligibility Criteria

Male or female participants from 40 years up to 75 years old.

Inclusion Criteria: - COPD (FEV1< 50%, Tiffeneau < 70%) - Dyspnoea on exertion and a reduced exercise capacity - Age 75 years or less - PaCO2 > 6.0 kPa at rest without oxygen Exclusion Criteria: - Cardial/neuromuscular diseases limiting a successful rehabilitation - Obstructive sleep apnoea syndrome: apnea/hypopnea index (AHI) > 10 - Previous exposure to chronic NIPPV - Participation in a pulmonary rehabilitation program less than 18 months ago

Additional Information

Official title Does Chronic Ventilatory Support Improve the Outcomes of Rehabilitation in Hypercapnic COPD Patients?
Principal investigator Marieke L Duiverman
Description Several randomised controlled trials in patients with stable Chronic Obstructive Pulmonary Disease (COPD) have demonstrated that pulmonary rehabilitation (PR) improves dyspnoea, exercise tolerance, and health-related quality of life. Research in this field has been important in our department for several years. The first study in this respect was started in 1986 comparing outpatient rehabilitation with rehabilitation in the community in patients with severe COPD. This study showed that rehabilitation supervised by a physical therapist in the community is effective for a long period in contrast to outpatient rehabilitation. In 1990 the second study started showing that positive initial benefits of home based rehabilitation on quality of life can be maintained for 18 months if the patients visit the local physical therapist once a month. However, less positive effects of rehabilitation have been reported in the more severe patients. Because of dyspnoea due to inspiratory muscle fatigue patients may not receive an adequate training stimulus, and therefore rehabilitation might be less effective. In these more severe patients alternative therapies are needed. These non-pharmacological treatments include nutritional supplementation, oxygen therapy, lung transplantation, lung volume reduction surgery and ventilatory support. The last few years a discussion within the 4 home mechanical ventilation centres (HMV) in the Netherlands has been started about the role of chronic ventilatory support in end-stage COPD. Theoretically, it might be effective because: 1. a resetting of the respiratory centre may reduce daytime PaCO2; 2. a better internal milieu (pH, PaO2, PaCO2) may improve peripheral muscle function; 3. resting the respiratory muscles during the night may increase their daytime strength and endurance; 4. a reduction in the number of nocturnal arousals may improve the quality of sleep. Nevertheless, none of these mechanisms has been proven and currently there is no evidence that noninvasive positive pressure ventilation (NIPPV) should be given to stable patients with COPD. While several randomised controlled trials (RCT’s) on NIPPV have been published with different outcomes, a recent meta-analysis did not show beneficial effects on blood gasses, lung function, respiratory muscle function and walking distance. In contrast several uncontrolled studies did show clear benefits from NIPPV on gas-exchange, dyspnoea and quality of life. Possible reasons for these conflicting outcomes are differences in: 1. selection of patients, 2. adequacy of ventilatory support, 3. length of ventilatory support. Interestingly, it seems that studies with a positive outcome included mainly patients with hypercapnia, suggesting this as an important selection criterion. The hypothesis is that long term NIPPV in hypercapnic patients with COPD may improve the effects of rehabilitation at home regarding health status, ADL function, dyspnoea and exercise tolerance. Secondly, we like to elucidate the exact mechanisms why NIPPV might be effective in this group of patients. Comparison: patients who receive noninvasive ventilation during the night while following a pulmonary rehabilitation program with patients who only follow a rehabilitation program without receiving the noninvasive ventilation.
Trial information was received from ClinicalTrials.gov and was last updated in April 2007.
Information provided to ClinicalTrials.gov by Groningen Research Institute for Asthma and COPD.